Key Points
- EVP Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam on Feb. 13 at an average of $310.08 for about $607,447, cutting his stake to 23,305 shares (a 7.75% drop); he also completed additional insider sales on Feb. 17, Jan. 13 and Jan. 12, and several other insiders — including the CEO — disclosed sales this week.
- Alnylam missed quarterly expectations, reporting $0.82 EPS vs. $1.43 expected and $1.10B revenue vs. $1.16B expected despite revenue rising 84.9% year-over-year, while the stock trades below its 50- and 200-day moving averages amid mixed analyst views (consensus price target ~ $477.96).
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Kevin Joseph Fitzgerald sold 1,959 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $607,446.72. Following the sale, the executive vice president directly owned 23,305 shares of the company's stock, valued at approximately $7,226,414.40. This trade represents a 7.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Kevin Joseph Fitzgerald also recently made the following trade(s):
- On Tuesday, February 17th, Kevin Joseph Fitzgerald sold 2,041 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $331.96, for a total value of $677,530.36.
- On Tuesday, January 13th, Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $370.33, for a total value of $848,055.70.
- On Monday, January 12th, Kevin Joseph Fitzgerald sold 1,510 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY opened at $332.61 on Wednesday. The firm has a fifty day moving average price of $371.01 and a 200 day moving average price of $424.25. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55. The stock has a market cap of $43.94 billion, a PE ratio of 194.51 and a beta of 0.35.
Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business's revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.65) earnings per share. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.
Key Alnylam Pharmaceuticals News
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Canaccord Genuity raised its price target to $429 and reaffirmed a "buy" rating, citing upside vs. the current price (Canaccord's note implies meaningful upside). Canaccord price-target raise
- Positive Sentiment: A MarketBeat-linked Motley Fool piece reports a pundit upgrade that helped lift sentiment and trading interest in ALNY. Why Alnylam Was Soaring
- Positive Sentiment: A bullish roundup in The Globe and Mail highlighted Alnylam among favorable healthcare ideas, supporting broader analyst-driven positivity. Analysts Are Bullish
- Neutral Sentiment: Short-interest data in the feed shows zero/NaN values and a 0.0 days-to-cover figure — likely a data/reporting artifact rather than new market pressure; treat as non-actionable until confirmed by an exchange report.
- Negative Sentiment: Multiple insider sales disclosed this week could weigh on sentiment: CEO Yvonne Greenstreet sold 6,958 shares at ~$310; several EVPs (Jeffrey Poulton, Kevin Fitzgerald, Tolga Tanguler, Pushkal Garg) sold mid‑hundreds to low‑thousands of shares at ~$310–332. These trades reduced insiders' stakes by mid-single-digit percentages. Filings: SEC links for the disclosures. Yvonne Greenstreet SEC filing Jeffrey Poulton SEC filing Kevin Fitzgerald filings Tolga Tanguler SEC filing Pushkal Garg SEC filing
- Negative Sentiment: Chardan Capital trimmed its price target to $425 (from a higher prior target), a modest negative datapoint that partly offsets other analyst optimism. Chardan target cut
Institutional Investors Weigh In On Alnylam Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Guggenheim Capital LLC increased its stake in Alnylam Pharmaceuticals by 365.3% during the fourth quarter. Guggenheim Capital LLC now owns 40,135 shares of the biopharmaceutical company's stock valued at $15,960,000 after purchasing an additional 31,510 shares during the last quarter. Caisse de depot et placement du Quebec boosted its holdings in shares of Alnylam Pharmaceuticals by 189.5% in the 4th quarter. Caisse de depot et placement du Quebec now owns 51,598 shares of the biopharmaceutical company's stock valued at $20,518,000 after buying an additional 33,772 shares during the period. Schonfeld Strategic Advisors LLC grew its position in shares of Alnylam Pharmaceuticals by 362.4% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 44,894 shares of the biopharmaceutical company's stock valued at $17,852,000 after buying an additional 35,185 shares during the last quarter. AQR Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 23.6% during the fourth quarter. AQR Capital Management LLC now owns 919,959 shares of the biopharmaceutical company's stock worth $365,822,000 after acquiring an additional 175,951 shares during the period. Finally, Abel Hall LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $442,000. 92.97% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently commented on ALNY. Morgan Stanley decreased their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating on the stock in a research note on Friday, January 30th. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an "outperform" rating and a $500.00 price target for the company. Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an "equal weight" rating on the stock in a research report on Tuesday, January 20th. Needham & Company LLC decreased their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a "buy" rating on the stock in a report on Thursday, February 12th. Finally, Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a "buy" rating in a report on Tuesday. Twenty-two equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $477.96.
Get Our Latest Stock Analysis on ALNY
About Alnylam Pharmaceuticals
(
Get Free Report)
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
